Structure Therapeutics shares soared 102% after it reported positive data from its Phase II ACCESS clinical program assessing its oral GLP-1 candidate aleniglipron in people with obesity and/or overweight with at least one weight related co-morbidity.The post StockWatch: Positive Obesity Pill Data Has Structure Investors Seeing Double appeared first on GEN - Genetic Engineering and Biotechnology News.
StockWatch: Positive Obesity Pill Data Has Structure Investors Seeing Double
